

Strategic Partners

Areas of Interest



Eli Lilly:

Discovery Research:

Protein expression/production/optimization technologies; Ab-drug conjugates; protein: protein interactions; drug delivery (across BBB; of nucleic acids)

CV:

LDL-C reduction for hypercholesterolemia; novel triglyceride lowering MOA; chronic kidney disease/diabetic nephropathy

Drug Delivery and Devices:

Auto-injector pens, wearable injectors; "Patch pump" delivery technology; oral peptide delivery technology; advances in Artificial Pancreas Device Systems; new tech to deliver therapeutic agents to CNS across BBB, needle-free technologies, transdermal patches, time-action modulation; delivery of multi-pharmacology at fixed or high doses of small and large molecules; medical algorithms for use in software apps

Oncology:

T-cell redirection and novel checkpoint agents; agents targeting tumor microenvironment and interplay between it and immune system; tumor metabolism pathway modulators; epigenetic modulators; NSCLC, SCLC; GI cancer; breast cancer

Diabetes:

Glucose control via insulins, soluble glucagon, incretins, tech/device/formulations; metabolic control via insulin sensitizers, modulation of white to brown adipose tissue conversion, pathway relating to lipotoxicity, immunometabolism, mitochondrial modulators; end organ protection: diabetic kidney disease, NASH, heart failure

Immunology:

Biologics related to RA, psoriasis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, lupus nephritis

Neuroscience:

Novel therapeutic approaches for disease modification or to address symptoms of Alzheimer's and Parkinson's Diseases; chronic neuropathic, inflammatory, visceral pain management

Roche:



Oncology: cancer immunotherapy, engage host immune response, systemic modulation of immunity, tumor targeted immune reaction

Infectious Disease: Broad spectrum antibiotics that are active against MDR gram-negative pathogens including E. coli, K. pneumoniae, A. baumannii, and P. aeruginosa.

Immunology/inflammation: Novel targets or pathways useful for multiple indications in inflammation/autoimmune disease such as lupus, psoriasis, inflammatory bowel disease, Sjogren's syndrome, etc.

Neuroscience: Neuroinflammation (including MS), neurodegeneration (including Alzheimer's disease and Parkinson's disease), neurodevelopmental disorders (including autism)

Rare Disease: Not ultra-rare diseases; monogenic diseases; diseases with significant unmet medical need where the treatment would be life-changing.

Ophthalmology: Focus on back of the eye disease, including age-related macular degeneration, diabetic retinopathy, diabetic macular edema, and glaucoma

Fibrosis: Particularly in the lung or liver.

Technology: Any game-changing innovation that allows us to access targets that have previously been inaccessible or to significantly improve how we use our therapeutic modalities (small molecules, biologics, and nucleic acids). Technologies that allow us to target nucleic acid therapeutics to specific cell types (especially outside the liver) and/or to release the oligos within cells.

Chembio:



Technologies that facilitate the development of Point of Care diagnostics that can improve sensitivity and specificity for specific biomarkers used in the detection of infectious disease, cancer, autoimmune diseases, cardiac and brain injury, etc. Technology can include new biomarkers, instrumentation to facilitate diagnosis, materials to improve assay performance or ease of use, etc.

Broadview Ventures:



Broadview's mission is to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments in and support of early stage ventures. Specific disease areas in which Broadview Ventures has invested include:

- Atrial Fibrillation
- Pulmonary Arterial Hypertension
- Myocardial Infarction
- Heart Failure
- Coronary Artery Disease
- Hypertension
- Stroke
- Valvular Disease
- Vascular Disease
- Preeclampsia
- Metabolic disorders (diabetes, obesity)
- Pediatric/congenital disorders